PMID- 25785658
OWN - NLM
STAT- MEDLINE
DCOM- 20160112
LR  - 20150416
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 17
IP  - 5
DP  - 2015 May
TI  - Interaction between exogenous insulin, endogenous insulin, and glucose in type 2 
      diabetes patients.
PG  - 335-42
LID - 10.1089/dia.2014.0326 [doi]
AB  - BACKGROUND: Little is known about the influence of exogenous insulin and actual 
      glucose levels on the release of endogenous insulin in insulin-treated type 2 
      diabetes mellitus (T2DM) patients. This study investigated the interaction among 
      serum endogenous insulin (s-EI), serum exogenous insulin aspart (s-IAsp), and 
      blood glucose levels in an experimental short-term crossover design. STUDY DESIGN 
      AND METHODS: Eight T2DM patients (63.52 years old; range, 49-69 years; mean body 
      mass index, 28.8+/-3.8 kg/m(2)) were randomized to treatment with individual fixed 
      doses of insulin aspart (0.5-1.5 IU/h) as a continuous subcutaneous insulin 
      infusion (CSII) during a 10-h period on two occasions with different duration of 
      hyperglycemia: (1) transient hyperglycemia for 2 h (visit TH) and (2) continuous 
      hyperglycemia for 12 h (visit CH). RESULTS: During steady state the variances of 
      plasma glucose (p-glucose), s-IAsp, and s-EI were equal within visit TH and 
      within visit CH, but variances were significantly higher during visit CH compared 
      with visit TH. The s-IAsp reached lower levels at visit CH compared with visit TH 
      (test for slope=1, P=0.005). The s-EI depended on p-glucose in a nonlinear 
      fashion during the first 100 min of both visits when s-IAsp was undetectable 
      (adjusted R(2)=0.9). A complex but statistically significant interaction among 
      s-IAsp, s-EI, p-glucose, and patients was observed during measurable s-IAsp 
      levels (adjusted R(2)=0.70). CONCLUSIONS: Endogenous and exogenous insulin showed 
      higher variation during continuous hyperglycemia. Significantly lower levels of 
      exogenous insulin were observed following CSII during continuous hyperglycemia 
      compared with transient hyperglycemia. Endogenous insulin levels could in a 
      complex way be explained by an individual interaction among p-glucose and serum 
      exogenous insulin, if present.
FAU - Janukonyte, Jurgita
AU  - Janukonyte J
AD  - 1 Department of Endocrinology and Internal Diseases, Aarhus University Hospital , 
      Aarhus, Denmark .
FAU - Parkner, Tina
AU  - Parkner T
FAU - Bruun, Niels Henrik
AU  - Bruun NH
FAU - Lauritzen, Torsten
AU  - Lauritzen T
FAU - Christiansen, Jens Sandahl
AU  - Christiansen JS
FAU - Laursen, Torben
AU  - Laursen T
LA  - eng
SI  - ClinicalTrials.gov/NCT01510093
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20150318
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
RN  - D933668QVX (Insulin Aspart)
SB  - IM
MH  - Aged
MH  - Blood Glucose/*drug effects
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*blood/drug therapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Hyperglycemia/*blood/drug therapy
MH  - Hypoglycemic Agents/*blood/therapeutic use
MH  - Infusions, Subcutaneous
MH  - Insulin/*blood
MH  - Insulin Aspart/administration & dosage/*blood
MH  - Male
MH  - Metformin/therapeutic use
MH  - Middle Aged
EDAT- 2015/03/19 06:00
MHDA- 2016/01/13 06:00
CRDT- 2015/03/19 06:00
PHST- 2015/03/19 06:00 [entrez]
PHST- 2015/03/19 06:00 [pubmed]
PHST- 2016/01/13 06:00 [medline]
AID - 10.1089/dia.2014.0326 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2015 May;17(5):335-42. doi: 10.1089/dia.2014.0326. Epub 
      2015 Mar 18.